摘要
目的探讨聚乙二醇洛塞那肽对肥胖2型糖尿病患者体质量、腰围和内脏脂肪面积(VFA)的影响。方法选择肥胖2型糖尿病患者90例,随机分为洛塞那肽组60例、二甲双胍组30例。洛塞那肽组予聚乙二醇洛塞那肽皮下注射,二甲双胍组予二甲双胍口服,两组均连续治疗8周。比较两组治疗前与治疗8周体质量、腰围、BMI、VFA、FPG、2 h PG、HbA1c、血脂(TC、TG、HDL-C、LDL-C)、肝功能(ALT、AST),以及治疗期间胃肠道不良反应情况。结果洛塞那肽组治疗后体质量、腰围、BMI、VFA较治疗前明显降低(P均<0.05);二甲双胍组治疗后体质量、腰围、BMI较治疗前明显降低(P均<0.05),而VFA与治疗前比较P>0.05;洛塞那肽组体质量、腰围、BMI和VFA降幅较二甲双胍组更明显(P均<0.05)。两组治疗后FPG、2 h PG、HbA1c较治疗前均明显降低(P均<0.05),但两组FPG、2 h PG、HbA1c降幅比较P均>0.05。洛塞那肽组治疗后TC、TG、HDL-C、LDL-C、ALT、AST较治疗前明显降低(P均<0.05);二甲双胍组治疗后HDL-C较治疗前明显降低(P<0.05),而TC、TG、LDL-C、ALT、AST与治疗前比较P均>0.05;洛塞那肽组TC、TG、LDL-C、ALT、AST降幅较二甲双胍组更明显(P均<0.05),而HDL-C降幅与二甲双胍组比较P>0.05。两组治疗期间不良反应发生率比较P>0.05。结论聚乙二醇洛塞那肽能够显著降低肥胖2型糖尿病患者体质量、腰围和VFA,其效果优于二甲双胍。
Objective To investigate the effects of polyethylene glycol loxenatide on body mass,waist circumference,and visceral fat area(VFA)in obese patients with type 2 diabetes.Methods Ninety obese patients with type 2 diabetes were randomly divided into the loxenatide group(60 cases)and metformin group(30 cases).Patients in the loxenatide group were injected with 0.2 mg polyethylene glycol loxenatide subcutaneously,once a week.Patients in the metformin group were given 0.5 g metformin orally,three times a day.Both groups were treated continuously for 8 weeks.The body mass,waist circumference,BMI,VFA,FPG,2 h PG,HbAlc,blood lipids(TC,TG,HDL-C,LDL-C),liver function(ALT,AST)and gastrointestinal adverse reactions during treatment were compared between the two groups before treatment and 8 weeks after treatment.Results The body mass,waist circumference,BMI and VFA of the loxenatide group after treatment were significantly lower than those before treatment(all P<0.05);the body mass,waist circumference and BMI of the metformin group after treatment were significantly lower than those before treatment(all P<0.05),while VFA was higher than that before treatment(P>0.05).Compared with metformin group,the decrease of body mass,waist circumference,BMI and VFA in the loxenatide group were more significant(all P<0.05).FPG,2 h PG and HbAlc in the two groups after treatment were significantly lower than those before treatment(all P<0.05),but no significant difference was found in the decrease of FPG,2 h PG and HbA1 c between the two groups(P>0.05).After treatment,TC,TG,HDL-C,LDL-C,ALT and AST in the loxenatide group were significantly lower than those before treatment(all P<0.05);HDL-C in the metformin group was significantly lower than that before treatment(P<0.05),while TC,TG,LDL-C,ALT,and AST were all higher than those before treatment(all P>0.05);the decrease of TC,TG,LDL-C,ALT and AST in the loxenatide group was more significant than that in metformin group(P<0.05),while no significant difference was found in the decrease of HDL-C b
作者
王燕
张秀娟
WANG Yan;ZHANG Xiujuan(Cheeloo College of Medicine,Shandong University,Jinan 250012,China;不详)
出处
《山东医药》
CAS
2022年第25期35-38,共4页
Shandong Medical Journal
基金
中华国际医学交流基金会森美中华糖尿病科研基金资助项目(Z-2017-26-1902-2)。
关键词
肥胖2型糖尿病
聚乙二醇洛塞那肽
二甲双胍
体质量
腰围
内脏脂肪面积
obesity type 2 diabetes
polyethylene glycol loxenatide
metformin
body mass
waist circumference
visceral fat area
